Mural Oncology plc (MURA) Short-Term Debt to Equity

Graphic logo of Mural Oncology plc (MURA)

The Mural Oncology plc (MURA) price chart demonstrates the 0.06 metric. Mural Oncology plc is implementing software robots and automated screening to accelerate drug development. However, the business faces significant cash burn and clinical trial uncertainty following its spin-off from Alkermes. The growth strategy relies on synergy with biotech centers to create modified cytokines tailored to the requirements of specialist physicians.

MURA - Mural Oncology plc Short-Term Debt to Equity Ratio over the range 02/21/2024 - 12/20/2025

Financial and market metric breakdowns for Mural Bio (MURA)

- stock quotes and analyst forecast:
Stock Price Mural Oncology plc|MURA - Analyst Consensus Forecast
- market capitalization details:
Market Value Mural Oncology PLC|MURA - Business Value
- balance sheet equity data:
Book Value per Share Mural Oncology|MURA - Company Net Assets|Market Capitalization to Book Value Ratio muraloncology.com|MURA - Company Assets
- business debt structure and liquidity details:
Debt to Equity Mural Oncology plc|MURA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Mural Oncology plc|MURA - Aggregate Debt Obligations|Debts to Book Capitalization Mural Oncology PLC|MURA - Company Long-Term Liabilities|Company Current Liabilities Mural Oncology|Quick Liquidity muraloncology.com
- earnings and market ratios statistics:
MURA - Final Profit
Fundamental valuation:Mural Oncology
Signature product of muraloncology.com

This indicator assesses the company's liquidity via the ratio of liabilities maturing within one year to equity, allowing for the determination of the business's dependence on rapid refinancing. By analyzing the level of short-term debt relative to equity, an investor can see how the lack of in-house manufacturing facilities at Mural Oncology (MURA) reduces capital expenditures, making a low debt load a guarantee of stability during drug development.

Competitors of Mural Oncology plc

Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|UroGen Pharma Ltd (URGN) - Short-Term Debt to Equity Ratio|BCAX: Short-Term Debt to Capital|Current Liabilities to Capital Personalis Genomics (PSNL)|Short-Term Debt to Equity Erasca, Inc.|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CADL (Candel Therapeutics, Inc.)|ARAY - Short-Term Debt to Equity Ratio|SLS: Short-Term Debt to Equity Ratio|ACTU - Short-Term Debt to Capital|Citius Oncology (CTOR) - Short-Term Debt to Equity|TuHURA Biosciences - Ratio of Short-Term Indebtedness to Capital|TARA (Protara) - Short-Term Debt to Capital|Current Liabilities to Capital Fate Pharma FATE|Short-Term Debt to Equity Aadi Bioscience Inc (WHWK)|Short-Term Debt to Equity Ratio tscan.com TCRX|Champions Oncology, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital XBiotech Inc XBIT|CVM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital OSTX (OS Therapies, Inc.)|RADX: Short-Term Debt to Capital|Artiva Biotherapeutics (ARTV) - Short-Term Debt to Capital|Short-Term Debt to Equity Adlai Nortye Ltd|Short-Term Debt to Equity VERU|Short-Term Debt to Equity Ratio TPST (Tempest Tx)|XLO (xiliotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Renovaro RENB|Kairos Pharma Limited (KAPA) - Current Liabilities to Capital|OKUR - Short-Term Debt to Equity|GDTC (CytoMed Therapeutics) - Short-Term Debt to Capital Ratio|CRIS: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Apollomics|Short-Term Debt to Equity Tharimmune, Inc.|Current Liabilities to Capital Advanced Biomed Corp ADVB|Short-Term Debt to Equity Genprex (GNPX)|Short-Term Debt to Equity CLDI (calidibio.com)|Short-Term Debt to Equity Sunshine Biopharma SBFM|Xenetic Biosciences Inc. (XBIO) - Current Liabilities to Capital|Salarius Pharmaceuticals - Short-Term Debt to Capital|Short-Term Indebtedness to Equity purple-biotech.com (PPBT)|AONC (aoncology.com) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital BeiGene Ltd. (BGNE)|Short-Term Debt to Equity Ratio CKPT|ELEV: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity iCAD, Inc. (ICAD)|IKNA: Current Liabilities to Equity|Short-Term Debt to Equity Notable Labs NTBL|Viracta Therapeutics Inc. - Short-Term Debt to Equity|MorphoSys Corp - Short-Term Debt to Capital|NAYA Biosciences Corp (NAYA) - Short-Term Debt to Equity Ratio|Ascentage Pharma Group (AAPGV) - Short-Term Debt to Equity